Dec 17 (Reuters) - Bayer AG :
* AFLIBERCEPT 8 MG MET PRIMARY ENDPOINT IN PHASE III STUDY AND DEMONSTRATES VISION GAINS WITH EXTENDED TREATMENT INTERVALS IN RETINAL VEIN OCCLUSION
* DETAILED RESULTS WILL BE SUBMITTED TO REGULATORY AUTHORITIES WORLDWIDE AND PRESENTED AT UPCOMING SCIENTIFIC MEETINGS
* APPROXIMATELY 90% OF AFLIBERCEPT 8 MG PATIENTS WERE EXTENDED TO EVERY 8-WEEK DOSING AND MAINTAINED THEIR INTERVAL THROUGH 36 WEEKS
* STUDY MET ITS PRIMARY ENDPOINT AT WEEK 36
Further company coverage:
(Gdansk Newsroom)
(((( gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments